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Recent high-throughput-sequencing of the cancer genome has identiﬁed oncogenic mutations in BRaf genetic locus as one of
the critical events in melanomagenesis. In normal cells, the activity of BRaf is tightly regulated. Gain-of-function mutations
like those identiﬁed in melanoma frequently lead to enhanced cell-survival and unrestrained growth. The activating mutation
of BRaf will also induce the cells to senesce. However, the mechanism by which the oncogenic BRaf induces the senescent barrier
remainspoorlydeﬁned.microRNAshaveregulatoryfunctionstowardtheexpressionofgenesthatareimportantincarcinogenesis.
Here we show that expression of several microRNAs is altered when the oncogenic version of BRaf is introduced in cultured
primary melanocytes and these cells undergo premature cellular senescence. These include eight microRNAs whose expression
rates are signiﬁcantly stimulated and three that are repressed. While most of the induced microRNAs have documented negative
eﬀects on cell cycle progression, one of the repressed microRNAs has proven oncogenic functions. Ectopic expression of some of
these induced microRNAs increased the expression of senescence markers and induced growth arrest and senescence in primary
melanocytes. Taken together, our results suggest that the change in microRNA expression rates may play a vital role in senescence
induced by the oncogenic BRaf.
1.Introduction
Unregulated oncogene expression during cancer develop-
ment causes cancer cells to senesce prematurely, a gene-di-
rected program that irrevocably induces cell cycle arrest [1–
4]. First described in cell culture [5], oncogene-induced
senescence (OIS) has been conﬁrmed in vivo as a vital
mechanism that constrains the malignant progression of
many tumors [3]. Unregulated oncoproteins promote senes-
cence by activating eﬀector pathways that are cell-type
and oncogene speciﬁc. Recent progress identiﬁed diﬀerent
regulatory circuitries of OIS, but much remains to be
learned [6]. High-throughput sequencing of the cancer
genomes has identiﬁed BRaf kinase as the most frequently
mutated (50–70%) oncogene in melanoma [7]. About 90%
of BRaf gain-of-function mutations are at position 600
with glutamic acid (E) inserted for valine (V) [7]. BRaf
is a serine/threonine protein kinase that functions directly
downstream of the small GTPase Ras and upstream of the
MEK and ERK mitogen-activated protein kinase (MAPK)
cascade. This mutation signiﬁcantly increases BRaf kinase
activity toward MEK, causing constitutive BRaf-MEK-ERK
signaling [7, 8]. The BRaf gain-of-function Val to Glu muta-
tion is required for cell viability, anchorage-independent
growth, and proliferation of BRaf
V600E-positive melanoma
cell lines in both cell-based studies and in vivo mouse
models [9–11]. Furthermore, a Phase I clinical trial with a
potentinhibitorofBRaf
V600E kinasedemonstratesthatBRaf-
mutant melanomas are highly dependent on BRaf kinase
activity [12]. Besides its frequent presence in melanoma,
BRaf
V600E mutations are also present in up to 82% of
melanocytic nevi with classical hallmarks of senescence
[13]. Importantly, sustained BRaf
V600E expression in human
melanocytes induces premature senescence [13]. The gain-
of-function mutation in BRaf may be the cause of growth2 International Journal of Cell Biology
arrest in nevi. Indeed, in studies with genetically modi-
ﬁed mouse models, the activated BRaf
V600E allele plays a
causal role in promoting benign melanocytic hyperplasia in
vivo [14, 15]. However the underlying mechanisms driv-
ing B-Raf
V600E-mediated senescence in melanocytes remain
undeﬁned.
MicroRNAs are small noncoding RNA species of 20–22
nucleotides that have critical functions across a myriad of
biological processes [16–19]. Aberrant expression of several
microRNAs has also been reported in melanocytic nevi [20].
In view of the emerging important role of microRNAs in
tumorigenesis and cell-cycle arrest, microRNAs may play a
causal role in BRaf
V600E-induced senescence in melanocytic
nevi. BRaf
V600E-induced senescence requires the activation
of a transcription program with multiple components [21–
23]. The mechanism that integrates the diverse components
into a coordinated response to the BRaf
V600E mutation
remains undeﬁned. Each microRNA targets ∼200 mRNA
molecules [18]. Because of their pleiotropic potentials,
microRNAs are attractive candidates as master regulators
of the premature senescence transcription program. In
this study, by ectopically expressing BRaf
V600E in primary
melanocytes, we identiﬁed 8 diﬀerent microRNAs whose
expressions were correlated with the BRaf gain-of-function
activity. Importantly, two of the identiﬁed microRNAs, when
expressed individually, are suﬃcient to induce premature
senescence in primary melanocytes in the absence of BRaf
mutation.
2. Results andDiscussion
To identify putative microRNAs involved in OIS, we
detected microRNAs induced by BRaf
V600E in melanocytes
using a focused PCR-based microarray system that enabled
assessment of 52 microRNAs (SABiosciences). As expected,
expression of BRaf
V600E in primary human melanocytes
induced constitutively high levels of ERK1/2 phosphory-
lation (Figure 1(a)) promoting growth arrest (Figure 1(b))
and senescence as detected by the expression of senescence-
associated β-galactosidase (SA-β-Gal) (Figure 1(c)), Dec1,
p16, p15, and DcR2 (Figures 1(a) and 1(d)). At a time
point prior to the detection of senescence, we collected
total RNA and enriched for small RNAs as recommended
by the manufacturer. By enriching for small RNAs, this
system is designed to detect mature microRNA expression
levels. The levels of each microRNA were quantiﬁed relative
to the levels of four control small RNAs. Among the 52
microRNAs that we examined, 13 were signiﬁcantly induced
and three (miR-10b, -15b, and -16) were greatly repressed
by BRaf
V600E in primary melanocytes (data not shown).
Subsequently, quantitative real-time PCR (qRT-PCR) was
used to further examine the eﬀect of BRaf
V600E on the
expression of these microRNAs with speciﬁc primers for
each individual microRNA. Eight out of the 13 that were
stimulated in the original screen were consistently induced
more than 2-fold by BRaf
V600E (Figure 2). Based on the
documented expression of these microRNAs in clinical
melanocytic nevi, we selected four of them for further study
[20, 24, 25].
To examine their causal role in cellular senescence in
melanocytes, we expressed individual microRNAs in pri-
mary human skin melanocytes by retroviral transduction.
The expression of microRNAs was conﬁrmed by qRT-
PCR with speciﬁc primers (Figure 3(a)). The eﬀects of
individual microRNA expression on the expression of ﬁve
senescence markers were determined by qRT-PCR (Figures
3(b)–3(e)). Three out of the four microRNAs tested had an
observable eﬀect on the expression of at least one of the
senescence markers. These are microRNAs 143, 34a, and 29a.
While expression of miR-34a increased p16INK4a, p15INK4b,
DcR2, and Dec1 transcripts, expression of miR-143, or 29a
increased the p15INK4b and DcR2 transcripts (Figures 3(c)–
3(e)). To investigate directly their role in cellular senescence,
we measured cell proliferation by quantifying the number of
melanocytes expressing the proliferation marker protein ki-
67 due to the expression of miR-143, 34a, or 29a. Expression
of miR-143 or -34a but not -29a or -100 led to a decrease
in melanocyte proliferation as measured by the expression
of proliferation marker protein ki-67. Importantly, the
decreased expression of ki-67 correlated with intense activity
of SA-β-Gal (Figure 3(f)).
Oncogenic BRaf induced premature senescence in
melanocyteswithaconcomitantincreaseintheexpressionof
senescence markers p16INK4a,p 1 5 INK4b, Dec1, and DcR2.
In addition, we showed that oncogenic BRaf also signiﬁ-
cantly increased the expression of miR-143, miR-34a, let-
7c, miR-15a, miR-29a, miR-100, miR-181a, and miR-181d.
By speciﬁc Watson-Crick base pairing between the seed
region of microRNA and sites within the mRNA 3 UTR,
each microRNA can potentially target diﬀerent groups of
mRNAs for regulation. Expression of miR-143, -34a, or -29a
led to the increased expression of some of the senescence
markers. It is therefore possible that a combined expression
of the identiﬁed microRNAs is responsible for the observed
upregulation of senescence markers in oncogenic BRaf
expressing melanocytes.
Among the microRNAs that are induced by the BRaf
gain-of-functionmutation,onlymiR-143or-34aissuﬃcient
to induce growth arrest and senescence when ectopically
expressed in primary melanocytes. miR-34a negatively reg-
ulates cell cycle G1/S transition genes cyclin D1, cyclin
E2, CDK4, and CDK6 and causes G1 arrest [26–28] when
expressed in human primary diploid ﬁbroblasts. In human
cancer cells, miR-143 is one of the most notable tumor
suppressor miR-RNAs, which can directly inhibit oncogene
KRAS translation and block the downstream signal pathways
[29]. Restoring miR-143 expression inhibited proliferation
and induced apoptosis by targeting BCL2 [30, 31]. In
agreement with these studies, we showed that miR-34a
or -143 induced premature senescence in primary human
melanocytes. Ectopic expression of miR-34a increased
expression of p16INK4a,p 1 5 INK4b, Dec1, and DcR2. Unlike
miR-34a, miR-143 only increased expression of p15INK4b
and DcR2. Since both miR-34a and -143 expression caused
senescence, it can be inferred that expression of p16INK4a orInternational Journal of Cell Biology 3
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Figure 1: Melanocytes were infected with control retroviral empty vector (EVC) or with a vector expressing BRaf
V600E.F o u rd a y sa f t e r
infection, cells were harvested for (a) immunoblotting with speciﬁc Abs as indicated or (d) total RNA. The expression levels of the indicated
senescence markers in BRaf
V600E expressing or control cells were quantiﬁed by qRT-PCR and normalized to the level of b-actin. The values
represent the means and standard deviation from three independent experiments. Cells were also isolated 4 days after infection, ﬁxed, and
stained for (b) ki-67 or (c) SA-β-Gal activity. Insets: representative ﬁelds are shown for control EVC and B-Raf
V600E expressing cells stained
with ki-67 Ab or positive for SA-β-Gal activity.4 International Journal of Cell Biology
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Figure 2: Melanocytes were infected with EVC or with vector expressing BRaf
V600E. Cells were harvested 4 days after infection and the
expression levels of the indicated miRNAs were quantiﬁed by qRT-PCR with speciﬁc primers (Biosciences) and normalized to the level of
U6 RNA. The values represent the means and standard deviation from three independent experiments.
Dec1isnotessentialforoncogenicBRaf-mediatedpremature
senescence. Concordantly, the presence of p16INK4a was also
previously found not to be required for senescence induced
by gain-of-function BRaf mutation in melanocytes [13]. It is
presentlynotclearwhichmRNAs,miR-34aor-143,targetfor
repression in melanocytes, nor do we know how oncogenic
BRaf induces their expression.
By targeting diﬀerent subset of genes for regulation,
microRNAs can function either as oncogenes or tumor sup-
pressor genes. As expected, all the identiﬁed induced miR-
RNAs have tumor suppressive functions. For instance, miR-
29, which has three family members, negatively impinges
on cancer cell survival by directly targeting the mRNAs of
the regulatory subunit of PI3 kinase (p85a) and CDC42
for regulation. miR-29a could also directly decrease CDK6
expression and cause G1/S growth arrest in [32]. Consistent
with its tumor suppressive role, miR-29 expression is fre-
quently downregulated in multiple cancers. However despite
its proven role in cell cycle regulation, expression of miR-
29a is not suﬃcient to induce senescence in melanocytes.
It is possible that miR-29a is required but not suﬃcient for
oncogenic BRaf-induced senescence. It is also possible that
the eﬀect of miR-29a on cell cycle progression is cell-context
dependent.International Journal of Cell Biology 5
We reason that if microRNA is part of the mechanism
that integrates the diverse components into a coordinated
response to the BRaf
V600E mutation, we should also observe
downregulation of oncogenic microRNAs. Indeed, miR-10b,
which increases the expression of oncogene RhoC by directly
targeting its transcriptional repressor HOXD10 [33], is con-
sistently repressed in melanocytes harboring the BRaf V600E
mutation. In addition to miR-10b, we also observed expres-
sion levels of miR-15b and -16 downregulated. miR-15/16
belongs to a very unique group of microRNAs. miR-16 has 2
transcripts—oneiscalledmiR-16-1locatedonChromosome
(Chr) 13 and shares the same transcript with miR-15a
forming the miR-15a/16 cluster. The other miR-16 is named
miR-16-2, which together with miR-15b is located at Chr
3 as the miR-15b/16 cluster. Interestingly while miR-15b
and 16 were downregulated, the miR-15a was upregulated
in melanocytes expressing BRaf V600E. Since our miR-16
primer detected both miR-16-1 and -16-2 transcripts, it is
unknown at present which miR-16 was downregulated by
oncogenic BRaf expression. The miR-15/16 family is known
to have a negative eﬀect on cell proliferation by targeting
mRNAs for various cell-growth-associated genes [34–36]. It
is therefore not clear why the downregulation of miR-15b
and -16 is favored in melanocytes, which are undergoing
senescence. Alternatively it is also possible that miR-5b/16
has unidentiﬁed oncogene targets.
Although it is clear that BRaf induces senescence in
melanocytes by activating MEK and ERK, the downstream
eﬀectors of its cytostatic eﬀect remain to be identiﬁed [13,
37]. BRaf V600E-mediated senescence also requires additional
eﬀector pathways involving several immune and growth
mediators such as IL6, IL8, and IGFBP7 [6]. However,
the mechanism that integrates the diverse pathways into
a coordinate response to oncogenic stimulation has not
been deﬁned. In this study, we identiﬁed several microRNAs
whose expression rates were stimulated by oncogenic BRaf.
Expression of four of these microRNAs induced the expres-
sion senescence-surrogate markers. Among them, miR-143
or -34a alone can induce growth arrest and senescence when
expressed in primary melanocytes.
Melanoma is a cancer of melanocytes and is the most
deadly form of skin cancer. The transformation of mel-
anocytes to malignant melanoma is a stepwise process fueled
by the accumulation of mutations in critical growth and
survival regulatory genes. The development of benign nevi
from melanocytes is the ﬁrst phenotypic change that can
be detected during the progression of normal melanocytes
to malignant melanoma. Studies with mouse models have
demonstrated the causal role of the activated BRaf V600E
allele in promoting benign melanocytic hyperplasia [14, 15].
The underlying mechanisms that drive the transformation of
melanocytes to a precancerous nevi are poorly understood.
Since microRNAs have multiple regulatory targets [18], our
results together with the expression of these microRNAs
in clinical melanocytic nevi [20] strongly suggest that
the identiﬁed microRNAs may play a vital coordinative
role in BRaf-induced senescence in melanocytic nevi. It is
conceivable that benign nevi transform into melanoma of
uncontrolled growth following subsequent mutations that
inactivate the oncogenic B-Raf-mediated senescence path-
ways. As such a thorough understanding of how oncogenic
BRaf inducessenescencewillallowustoelucidatethemolec-
ular mechanisms that drive the conversion of melanocytes to
preneoplastic nevi and transition to melanoma.
3.MaterialsandMethods
3.1. Cell Lines and Reagents. Human melanocytes were from
Cascade Biologics (Portland, OR, USA) or Yale Cell Culture
Core Facility. Human melanocytes were grown in Media 254
with added growth supplements (Cascade Biologics).
3.2. Plasmid Constructs. Retroviral expression vectors (miR-
vec) for miR-100, miR-15a/16-1, and -181a were a kind
gift of Reuven Agami. The miRNA minigenes -29a, -34a, -
143, -181d, -15b, and -15b/16-2 were PCR ampliﬁded from
genomic human DNA, cloned downstream of the CMV
promoter in miR-vec, and sequence veriﬁed. The primers for
the miRNA minigenes cloning were the following:
miR-29a Forward: 5 -gcGGATCCCTGGAACCAA-
TCCCTCAA
miR-29a Reverse: 5 -gcGAATTCGCTCCTTTCC-
CATCATCT
miR-34a Forward: 5 -gcGGATCCGGCTGGTCTT-
GAACTCCT
miR-34a Reverse: 5 -gcGAATTCCACTGGCTAC-
TATTCTCCCTA
miR-143 Forward: 5 -gcGGATCCTCAAGGTTTG-
GTCCTGGGTG
miR-143 Reverse: 5 -gcGAATTCCGTGAAGCAG-
ATCGTGGC
miR-15b Forward: gcggatccAAGGGGATGATTA-
TGAAG
miR-15b Reverse: gcgaattcAGTGGAACAAGTA-
TGTCAGT
miR-15b/16 Forward: gcggatccGACTTGGACCATA-
ATAGA
miR-15b/16 Reverse: gcgaattcTAGGTGCTTAGGT-
AAATC
miR-181d Forward: gcggatccGACCGTTGAGTGG-
ACCC
miR-181d Reverse: gcgaattcTCCAGCCAGAGCC-
CATCC
3.3. Isolation of Genomic DNA from Primary Melanocytes.
One 10cm cultured plate of subconﬂuent primary
melanocytes was harvested by trypsin digestion. Trypsin was
subsequently neutralized and cells were collected by
centrifugation and washed with PBS. The washed cell-pellet
was resuspended with 1.2mL cell resuspension buﬀer
(10mM Tris-HCL, 10mM NaCl, 1.5mM MgCl2) by gently6 International Journal of Cell Biology
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Figure 3: Melanocytes were infected with EVC or with vector expressing the indicated miRNA. (a) Quantiﬁcation of miRNAs expression by
qRT-PCR in indicated miRNA expressing cells. (b)–(e) The expression levels of the indicated senescence markers in the indicated miRNA
expressing cells were quantiﬁed by qRT-PCR and normalized to the level of b-actin. The values represent the means and standard deviation
from three independent experiments. Cells infected with the indicated miRNA expressing virus were also isolated after selection, ﬁxed, and
stained for (f) ki-67 or (g) SA-β-Gal activity.
pipetting up and down. Cells were digested with 8mL of
sucrose/proteinase K lysis buﬀer (27% sucrose, 1xSSC,
1mM EDTA, 1%SDS, 200ug/mL proteinase K) overnight at
37◦C. The next day digested cells were extracted with 10mL
phenol: chloroform: isoamyl alcohol (25:24:1) and the
DNA was precipitated with 1 volume isopropanol. DNA was
dissolved and extracted with phenol/chloroform/isoamyl
alcohol again followed by precipitation with 1/3 volume of
7.5M ammonium acetate (pH 7.4). Precipitated DNA was
washed with 70% ethanol and dissolved in TE (pH 7.4).
3.4. Analysis of SA-b-Galactosidase Activity. The senescence-
associatedb-galactosidaseactivityinculturecellwasdetected
with a staining kit purchased from Cell Signaling Technology
according to the manufacturer’s speciﬁcations.
3.5. Ki-67 Staining. Cells were plated on laminin-coated
cover slips (Laminin, L 2020, SIGMA). After 48 hours, cells
were washed with PBS and ﬁxed with 100% cold Methanol
for 10 minutes. Fixed cells were then incubated in blocking
solution (0.1% BSA in PBS) for 30 minutes. Primary anti-
bodies, 200–300μL (1:100 in block solution), speciﬁc for ki-
67 (sc-15402, Santa Cruz) were added onto each cover slips
and incubated overnight at 4◦C. Primary antibody-stained
cells were washed 3 times for 3 minutes each with 0.1%
BSA-PBS blocking solution. Washed cells were subsequently
incubated with FITC-conjugated secondary antibody (1:200
diluted in blocking solution) for 1 hour at room temperature
followed by one wash with blocking solution for 3 minutes,
two PBS washes for 3 minutes each, and two washes with
dH2O. The nuclei of ki-67 stained cells were visualized with
DAPI (4 μg/mL in dH2O) staining for 10min. Cells were
rinsed with dH2O twice before mounting onto glass slides
with DAKO ﬂuorescent mounting medium (Dako, s3032).
The glass slides were dried in the hood for 5–10 minutes.
The cover slip edges were sealed with nail enamel polisher
and were dried in the hood for an addition 10–20min.
3.6. Antibodies. The BRaf polyclonal antibodies were from
Upstate (number 07-453). The Phospho-p44/42 MAPK
(Thr202/Tyr204) (E10) Mouse mAb (number 9106) and
p44/42 MAP Kinase Antibodies (number 9102) were from
Cell Signaling. Dec1 (s-8) (sc-101023), p16 (JC8) (sc-
56330), and p15 (C-20) (sc-612) antibodies were from Santa
Cruz. DcR2 Polyclonal Antibody (AAP-371) was from Assay
designs. Monoclonal anti-α Tubulin Clone B-5-1-2 (T-5168)
was from SIGMA.
3.7. Quantitative Real-Time RT-PCR. Total cellular RNA
was extracted with the Trizol reagent (Invitrogen) and
reverse transcribed using random hexamer primers (Applied
B i o s y s t e m s ) .T h er e s u l t i n gc D N A sw e r eu s e df o rP C Ru s i n g
SYBR-Green Master PCR mix (QIAGEN) in triplicates. PCR
and data collection were performed on ABI7500 (Applied
Biosystems). β-actin, GAPDH, and HPRT were used as an
internal standard. The gene-speciﬁc primers were as follows:
human p14
R: 5 -CATGACCTGGTCTTCTAGGAAGC-3 
F: 5 -CCCTCGTGCTGATGCTACTGA-3 
human p15
R: 5 -GCATGCCCTTGTTCTCCTCG-3 
F: 5 -GGGAAAGAAGGGAAGAGTGTCGTT-
3 
human p16
R: 5 -GGTTGTGGCGGGGGCAGTT-3 
F: 5 -GGGGGCACCAGAGGCAGT-3 8 International Journal of Cell Biology
human DcR2
R: 5 -CCGGGGGATGGTGGCAGAGT-3 
F: 5 -CGCTCGAGCAGGGCGCTATC-3 
human Dec1
R: 5 -CGATGAGCCGGTGCGGCAAT-3 
F: 5 -CCGGGACTGGAGCACGGAGA-3 
b-actin
F: 5 -ATCTGGCACCAGACCTTCTACAAT-
GAGCTGCG-3 
R: 5 -CGTCATACTCCTGCTTGCTGATCC-
ACATCTGC-3 
glyceraldehyde-3-phosphate dehydrogenase
F: 5 -TGCACCACCAACTGCTTAGC-3 
R: 5 -GGCATGGACTGTGGTCATGAG-3 
3.8. Real-Time PCR to Check Expression Levels of miRNAs.
cDNA from the obtained miRNAs was synthesized using RT2
miRNA ﬁrst strand kit (SABiosciences). Amount of miRNA
used was 200ng. The cDNA was then ampliﬁed using
miRNA-speciﬁc primer. RNU6, SNORD 44, and SNORD 48
were used as controls. Real-time PCR results were analyzed
using the ddCT method.
3.9. Isolation of miRNA. Small RNA from primary mel-
anocytes was prepared using RNeasy Mini kit protocol
(Qiagen). Cells were harvested for RNA using TRIzol
(Invitrogen). Chloroform was added to the tubes containing
homogenate (20% of the volume of TRIzol used). After
shaking the tubes vigorously, the tubes were incubated at
RT for 2-3 minutes and centrifuged (12,000×g) for 15mins
at 4◦C. The upper aqueous layer was transferred to new
tubes and 1 volume of 70% ethanol was added. The sample
was mixed and applied to the RNeasy minispin column and
centrifugedat8000×g(10,000rpm)for15satRT.Thelarger
RNAs are bound to the column ﬁlter. The ﬂow-through
contained miRNAs and was further puriﬁed according to the
manufacturer’s speciﬁcations (Qiagen).
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